TORONTO, Canada/MEDELLIN, Colombia, Dec. 12, 2016 /CNW/ - PharmaCielo Ltd. President and CEO Dr. Patricio Stocker is pleased to announce the establishment of a research partnership with the Universidad CES based in Medellin, Colombia.
Founded in Medellin in 1977, Universidad CES offers advanced graduate-level degree programs through a number of faculties which complement PharmaCielo's focus on being the global leader in the research and development of medicinal-grade cannabis oil extracts. The Universidad CES provides the opportunity to work together with leading scientists and academics.
"We are delighted to announce a partnership with the Universidad CES," said Stocker. "As a leading educational institution with a commitment to advancing research, education and social impact, the modern facilities and laboratories at Universidad CES provide significant opportunity for PharmaCielo and university faculty to vigorously investigate the efficacy of cannabis oil extracts in pre-clinical and clinical research platforms."
PharmaCielo's recently announced Medical Advisory Board is expected to work in close partnership with their colleagues at Universidad CES.
"This partnership with PharmaCielo will create new opportunities for our faculty to pursue novel research in a manner that will bring considerable benefit to our students as well as the local and global community," said Dr. Jorge Osorio, Rector of Universidad CES.
About Universidad CES
CES is a private, national, autonomous, non-denominational, non-profit, self-sustainable university that forms professionals with the highest human, ethical and scientific qualities in numerous areas of knowledge with a special emphasis in health-related programs. CES offers undergraduate and postgraduate educational programs at a technological and professional level, stimulating cultural, social, ideological, political and religious pluralism.
About PharmaCielo Ltd:
PharmaCielo Ltd. is a global company privately held and headquartered in Canada, with a focus on processing and supplying all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo's principal (and wholly-owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its Nursery and Propagation Centre located in Rionegro, Colombia.
The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia's ideal location will play in building a sustainable business in the medical cannabis industry, and the company, together with its directors and executives, has built a compelling business plan focused on supplying the international marketplace.
This press release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or "recurring" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as demand for the Company's products, currency exchange changes and risks, internal funding and the financial condition of the Company, product roll-out, competition, technological changes, and other commercial matters involving the Company, its products, and the markets in which the Company operates, as well as general economic conditions, which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this press release. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. However, any further disclosures made on related subjects in subsequent reports should be consulted.
For further information: www.PharmaCielo.com; Media Relations: David Gordon, Tel: +1 647 259 3258, David.Gordon@CohnWolfe.ca; (Colombia) Juan Manuel Cuellar, Tel: +57 310 3298776, Juan.M.Cuellar@Sprgroup.biz; Investor Inquiries: Tel: +1 647 560 4640, Toll Free 888 968 8279, Investors@PharmaCielo.com